This has led to investigations into the use of thrombolytic agents, such as tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), in the early management of IVH to reduce the incidence of hydrocephalus. This evidence concerns the gene PLAU and Hydrocephalus.